Drugs / CART123
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07464951 | May 2026 → May 2029 expected | acute myeloid leukemia | Stephan Grupp MD PhD | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03556982 | Mar 2018 → Mar 2019 | acute myeloid leukemia | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07464951 ↗ |
| Modality | Cell therapy | “CD123-Targeted CAR-T cells” NCT03556982 ↗ |
| Route | Other | “are infused” NCT03556982 ↗ |